Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

mRNA vaccination with charge-altering releasable transporters elicits human T cell responses and cures established tumors in mice.

Haabeth OAW, Blake TR, McKinlay CJ, Waymouth RM, Wender PA, Levy R.

Proc Natl Acad Sci U S A. 2018 Sep 25;115(39):E9153-E9161. doi: 10.1073/pnas.1810002115. Epub 2018 Sep 10.

2.

Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity.

Fotin-Mleczek M, Duchardt KM, Lorenz C, Pfeiffer R, Ojkić-Zrna S, Probst J, Kallen KJ.

J Immunother. 2011 Jan;34(1):1-15. doi: 10.1097/CJI.0b013e3181f7dbe8.

PMID:
21150709
3.

Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy.

Van Lint S, Goyvaerts C, Maenhout S, Goethals L, Disy A, Benteyn D, Pen J, Bonehill A, Heirman C, Breckpot K, Thielemans K.

Cancer Res. 2012 Apr 1;72(7):1661-71. doi: 10.1158/0008-5472.CAN-11-2957. Epub 2012 Feb 15.

4.

Vaccine therapy of established tumors in the absence of autoimmunity.

Hodge JW, Grosenbach DW, Aarts WM, Poole DJ, Schlom J.

Clin Cancer Res. 2003 May;9(5):1837-49.

5.

Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma.

Goforth R, Salem AK, Zhu X, Miles S, Zhang XQ, Lee JH, Sandler AD.

Cancer Immunol Immunother. 2009 Apr;58(4):517-30. doi: 10.1007/s00262-008-0574-6. Epub 2008 Aug 22.

PMID:
18719913
6.

mRNA Cancer Vaccines.

Fiedler K, Lazzaro S, Lutz J, Rauch S, Heidenreich R.

Recent Results Cancer Res. 2016;209:61-85. doi: 10.1007/978-3-319-42934-2_5. Review.

PMID:
28101688
7.
8.

Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect.

Fotin-Mleczek M, Zanzinger K, Heidenreich R, Lorenz C, Thess A, Duchardt KM, Kallen KJ.

J Gene Med. 2012 Jun;14(6):428-39. doi: 10.1002/jgm.2605.

PMID:
22262664
9.

The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors.

Kudo-Saito C, Schlom J, Camphausen K, Coleman CN, Hodge JW.

Clin Cancer Res. 2005 Jun 15;11(12):4533-44.

10.

Vaccination with liposome--DNA complexes elicits enhanced antitumor immunity.

U'Ren L, Kedl R, Dow S.

Cancer Gene Ther. 2006 Nov;13(11):1033-44. Epub 2006 Jul 14.

PMID:
16841080
11.

mRNA Vaccine with Antigen-Specific Checkpoint Blockade Induces an Enhanced Immune Response against Established Melanoma.

Wang Y, Zhang L, Xu Z, Miao L, Huang L.

Mol Ther. 2018 Feb 7;26(2):420-434. doi: 10.1016/j.ymthe.2017.11.009. Epub 2017 Nov 21.

12.

The hemagglutinin-neuraminidase gene of Newcastle Disease Virus: a powerful molecular adjuvant for DNA anti-tumor vaccination.

Ni J, Schirrmacher V, Fournier P.

Vaccine. 2010 Oct 4;28(42):6891-900. doi: 10.1016/j.vaccine.2010.08.011. Epub 2010 Aug 13.

PMID:
20709006
13.

Direct T cell activation via CD40 ligand generates high avidity CD8+ T cells capable of breaking immunological tolerance for the control of tumors.

Soong RS, Song L, Trieu J, Lee SY, He L, Tsai YC, Wu TC, Hung CF.

PLoS One. 2014 Mar 24;9(3):e93162. doi: 10.1371/journal.pone.0093162. eCollection 2014.

15.

Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.

Karan D, Dubey S, Van Veldhuizen P, Holzbeierlein JM, Tawfik O, Thrasher JB.

Immunotherapy. 2011 Jun;3(6):735-46. doi: 10.2217/imt.11.59.

PMID:
21668311
16.

Vaccination with poly-L-arginine as immunostimulant for peptide vaccines: induction of potent and long-lasting T-cell responses against cancer antigens.

Mattner F, Fleitmann JK, Lingnau K, Schmidt W, Egyed A, Fritz J, Zauner W, Wittmann B, Gorny I, Berger M, Kirlappos H, Otava A, Birnstiel ML, Buschle M.

Cancer Res. 2002 Mar 1;62(5):1477-80.

17.
19.

Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation.

Hobo W, Novobrantseva TI, Fredrix H, Wong J, Milstein S, Epstein-Barash H, Liu J, Schaap N, van der Voort R, Dolstra H.

Cancer Immunol Immunother. 2013 Feb;62(2):285-97. doi: 10.1007/s00262-012-1334-1. Epub 2012 Aug 19.

PMID:
22903385
20.

Trypanosoma cruzi as an effective cancer antigen delivery vector.

Junqueira C, Santos LI, Galvão-Filho B, Teixeira SM, Rodrigues FG, DaRocha WD, Chiari E, Jungbluth AA, Ritter G, Gnjatic S, Old LJ, Gazzinelli RT.

Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):19695-700. doi: 10.1073/pnas.1110030108. Epub 2011 Nov 23.

Supplemental Content

Support Center